Zai Lab Partner MacroGenics Announces FDA Approval of MARGENZA™ for Patients with Pretreated Metastatic HER2-Positive Breast Cancer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/9/2026

1. BRZE
2. TTAN
3. AAPL
4. CHYM
5. USO
6. IRT
7. QCOM
8. ASO
9. LAES
10. NTHI

Go back to Zai Lab Partner MacroGenics Announces FDA Approval of MARGENZA™ for Patients with Pretreated Metastatic HER2-Positive Breast Cancer
MACROGENICS (NASDAQ: MGNX) Delayed: 4.13 -0.19 (4.4%)
Previous Close $4.32    52 Week High $36.11 
Open $4.29    52 Week Low $14.84 
Day High $4.30    P/E 10.59 
Day Low $4.03    EPS $0.39 
Volume 437,882